5ALPHA-REDUCTASE INHIBITORS FOR REDUCT OF PROSTATE EPITHELIAL CELL GROWTH

5 种用于减少前列腺上皮细胞生长的α-还原酶抑制剂

• 批准号: 8360341
• 负责人: BRIAN L LINDSHIELD
• 金额: $ 8.46万
• 依托单位: KANSAS STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2013-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8360341
• 关键词: American; Androgens; Automobile Driving; Benign Prostatic Hypertrophy; Botanicals; Cell Proliferation; Chibro-Proscar; Development; Diagnosis; Disease; Dutasteride; Effectiveness; Enzymes; Epithelial; Epithelial Cells; Finasteride; Funding; GlaxoSmithKline brand of dutasteride; Grant; Growth; Health; Malignant Neoplasms; Malignant neoplasm of prostate; National Center for Research Resources; Nutrient; Oxidoreductase; Principal Investigator; Prostate; Public Health; Reporting; Research; Research Infrastructure; Resources; Sabal serrulata; Sales; Saw palmetto extract; Source; Stanolone; Testosterone; Therapeutic; United States National Institutes of Health; cell growth; combat; cost; implantation; inhibitor/antagonist; male; men; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Prostate cancer is the most commonly diagnosed male cancer. Thus, preventative and/or therapeutic strategies to combat this cancer could have a profound impact on public health. The 5¿-reductase inhibitors finasteride (Proscar¿) and dutasteride (Avodart¿) are commonly used to treat benign prostatic hyperplasia (BPH), but may also potentially decrease the development and/or progression of prostate cancer. 5¿-reductase enzymes convert testosterone to the more potent androgen dihydrotestosterone, which is important for driving the growth of most prostate cancers. Specific Aim 1 will examine the effectiveness of finasteride and dutasteride when begun before or after tumor implantation. Saw palmetto extracts have also been used to treat BPH and are reported to decrease 5¿-reductase enzymes, but there has been a lot of inconsistency their reported effectiveness. Despite the saw palmetto's questionable effectiveness, it is commonly used by Americans, ranking in the top 5 of botanical sales and is commonly used by men with prostate cancer. We believe that the variable results between studies may be due to differences in the extracts nutrient profiles, which have been reported to vary widely. Specific Aim 2 we will collect commonly used commercial saw palmetto extracts and characterize their nutrient profiles. We will then determine whether an extract's nutrient profile correspond to its ability to inhibit 5¿-reductase and cell proliferation of prostate cancer epithelial cells.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 前列腺癌是最常见的男性癌症。因此，防治这种癌症的预防和/或治疗策略可能对公共卫生产生深远影响。第五章- 还原酶抑制剂非那雄胺（Proscar <$）和度他雄胺（Avodart <$）通常用于治疗良性前列腺增生（BPH），但也可能潜在地减少前列腺癌的发展和/或进展。5¿- 还原酶将睾酮转化为更有效的雄激素二氢睾酮，这对驱动大多数前列腺癌的生长很重要。具体目标1将检查在肿瘤植入之前或之后开始使用非那雄胺和度他雄胺的有效性。锯棕榈提取物也被用于治疗BPH，据报道可以降低5-还原酶，但其报道的有效性存在很多不一致。尽管锯棕榈的有效性值得怀疑，但它被美国人普遍使用，在植物销售中排名前5位，并且通常被前列腺癌患者使用。我们认为，研究之间的可变结果可能是由于提取物营养成分的差异，这已被报道有很大的差异。具体目标2，我们将收集常用的商业锯棕榈提取物和表征其营养概况。然后，我们将确定提取物的营养成分是否与其抑制5-还原酶和前列腺癌上皮细胞增殖的能力相对应。